Clinical Trials
37 trialsNCT02860000 2026-02-27
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
Mayo Clinic
Phase 2 Completed
NCT04555837 2025-05-20
Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01848067 2025-05-04
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Thomas Jefferson University
Phase 1/2 Completed
NCT02186509 2025-04-30
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Thomas Jefferson University
Phase 1 Completed
NCT02187991 2024-10-09
Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
US Oncology Research
Phase 2 Completed
NCT02293005 2022-10-04
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02719691 2022-07-25
Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer
University of Colorado, Denver
Phase 1 Completed
NCT00853307 2022-04-08
MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Takeda
Phase 2 Completed
NCT02530619 2021-05-26
Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
Northwestern University
Phase NA Unknown
NCT01154816 2020-05-13
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Children's Oncology Group
Phase 2 Completed
NCT02560025 2020-05-05
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
Massachusetts General Hospital
Phase 2 Completed
NCT02327169 2020-02-25
A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
Takeda
Phase 1 Completed
NCT02259010 2019-09-20
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Takeda
Phase 1 Completed
NCT01601535 2019-07-31
Study of MLN8237 in Combination With Irinotecan and Temozolomide
New Approaches to Neuroblastoma Therapy Consortium
Phase 1/2 Completed
NCT02367352 2019-06-26
Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors
Takeda
Phase 1 Terminated
NCT01898078 2019-06-21
Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas
Takeda
Phase 1 Completed
NCT00697346 2019-05-31
Study of MLN8237 in Participants With Advanced Hematological Malignancies
Takeda
Phase 1 Completed
NCT01844583 2019-03-25
Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
Takeda
Phase 1 Completed
NCT00651664 2019-03-15
A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies
Takeda
Phase 1 Completed
NCT01512758 2019-03-15
A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas
Takeda
Phase 1 Completed
NCT00500903 2019-03-14
A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT00962091 2019-03-12
Study of MLN8237 in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT01094288 2019-02-15
A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
Takeda
Phase 1 Completed
NCT02038647 2018-12-27
Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
Takeda
Phase 2 Completed
NCT02214147 2018-11-15
Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function
Takeda
Phase 1 Completed
NCT01714947 2018-10-31
Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib
Takeda
Phase 1 Completed
NCT01482962 2018-07-31
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Takeda
Phase 3 Completed
NCT01812005 2018-06-06
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT01091428 2018-06-04
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Takeda
Phase 2 Completed
NCT00830518 2018-05-11
A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
Takeda
Phase 2 Completed
NCT00807495 2018-03-27
Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma
Takeda
Phase 2 Completed
NCT01397825 2018-03-27
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine
Takeda
Phase 1/2 Completed
NCT01799278 2018-01-23
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Weill Medical College of Cornell University
Phase 2 Completed
NCT01653028 2017-11-30
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01045421 2016-08-15
Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
Millennium Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01034553 2016-05-25
Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT01466881 2016-03-10
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed